A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
COOPER COMPANIES, INC.
COO
$14.1B
Mkt Cap
$70.31
+0.11%
COOPER COMPANIES, INC. (COO) has a current P/E ratio of 37.6, compared to its historical median P/E of 36.9. The stock is currently considered Fair based on its historical valuation range.
COOPER COMPANIES, INC. (COO) has a 5-year average return on invested capital (ROIC) of 12.1%. This indicates solid capital allocation.
COOPER COMPANIES, INC. (COO) has a market capitalization of $13.7B. It is classified as a large-cap stock.
COOPER COMPANIES, INC. (COO) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.61%.
Based on historical P/E analysis, COOPER COMPANIES, INC. (COO) appears fair. The current P/E of 37.6 is 2% above its historical median of 36.9. The estimated fair value CAGR (P/E method) is -3.2%.
COOPER COMPANIES, INC. (COO) operates in the Ophthalmic Goods industry, within the Healthcare sector.
COOPER COMPANIES, INC. (COO) reported annual revenue of $4.1 billion in its most recent fiscal year, based on SEC EDGAR filings.
The Cooper Companies is a global medical device company operating through two segments: CooperVision and CooperSurgical. CooperVision is the world's leading contact lens manufacturer, offering a broad portfolio of single-use, two-week, and monthly silicone hydrogel lenses across spherical, toric, and multifocal categories, as well as specialty products including myopia management lenses (MiSight 1 day, the first and only FDA-approved contact lens for slowing myopia progression in children aged 8–12) and orthokeratology lenses, with major manufacturing facilities in Belgium, Costa Rica, Hungary, Puerto Rico, the United Kingdom, and the United States, serving over 130 countries and impacting more than fifty million lives annually. CooperSurgical provides a diversified portfolio of over 600 products and services focused on fertility and women's health, including gynecology and obstetrics devices, contraception (Paragard IUD), cord blood and tissue cryostorage, and fertility solutions such as IVF media, micro-tools, lab equipment, donor gametes, and genomic services, distributed through OB/GYN offices, hospitals, ambulatory surgery centers, and fertility clinics with facilities in Costa Rica, the Netherlands, the United Kingdom, and the United States. Both segments compete on product quality, differentiation, technological innovation, pricing, and service levels in highly competitive markets characterized by consolidation trends toward group practices and integrated delivery networks, with CooperVision facing competition from Johnson & Johnson Vision Care, Alcon, and Bausch + Lomb, while CooperSurgical operates in selected fertility and women's health segments with a focus on key accounts and integrated solutions.
【Asia-Pacific stabilization ahead】 Management expects CooperVision's Asia-Pacific region, which has faced softness from market weakness and legacy product rationalization, to stabilize and return to growth in the second half of fiscal 2026 as new regional leadership executes on product launches and contract wins. The company anticipates the global contact lens market will grow at the low end of the historical 4%–6% range, with regional softness in Asia-Pacific viewed as temporary and tied to economic pressures in China and Japan rather than fundamental demand deterioration. CooperSurgical's fertility business is expected to rebound with mid-single-digit growth in the back half of 2026, supported by improving clinic investment cycles, delayed childbirth trends, and expanding access to care, while the long-term outlook remains positive driven by a strong innovation pipeline and increasing awareness of fertility solutions. The company is pursuing disciplined capital allocation, prioritizing share repurchases and debt reduction while continuing to invest in growth initiatives and operational efficiency improvements through AI-enabled systems and supply chain optimization.
| Metric | Target | Period |
|---|---|---|
| Revenue | $4.28 billion–$4.32 billion | FY2026 |
| CooperVision Revenue | $2.88 billion–$2.91 billion | FY2026 |
| CooperSurgical Revenue | $1.4 billion–$1.41 billion | FY2026 |
| EPS | $4.58–$4.66 | FY2026 |
| Free Cash Flow | ~$650 million | FY2026 |
| Interest Expense | ~$85 million | FY2026 |
| Effective Tax Rate | ~15.5% | FY2026 |
| Tariff Impact | ~$22 million | FY2026 |
| CooperVision Organic Growth | 3.5%–4.5% | FY2026 |
| CooperSurgical Organic Growth | 4%–5% | FY2026 |
| MiSight Growth | 20%–25% |
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q2 FY2026 Earnings Call, Q1 FY2026 Earnings Call, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 4.2B | 4.1B | 3.9B | 3.6B | 3.3B | 2.9B |
| Net Income | 236M | 375M | 392M | 294M | 386M | 2.9B |
| EPS | $1.20 | $1.87 | $1.96 | $1.49 | $1.95 | $14.79 |
| Free Cash Flow | 570M | 434M | 288M | 215M | 450M | 524M |
| ROIC | 2.7% | 4.3% | 4.6% | 3.8% | 4.5% | 43.5% |
| Gross Margin | 65.5% | 65.5% | 66.6% | 65.6% | 64.7% | 66.9% |
| Debt/Equity | 0.30 | 0.31 | 0.32 | 0.35 | 0.44 | 0.21 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.02 | $0.02 | $0.02 |
| Operating Income | 498M | 683M | 706M | 533M | 508M | 506M |
| Operating Margin | 11.8% | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% |
| ROE | 2.9% | 4.6% | 5.0% | 4.0% | 5.5% | 54.7% |
| Shares Outstanding | 195M | 200M | 200M | 198M | 197M | 199M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 1.7B | 1.8B | 2.0B | 2.1B | 2.5B | 2.7B | 2.4B | 2.9B | 3.3B | 3.6B | 3.9B | 4.1B | 4.2B |
| Gross Margin | 63.5% | 59.6% | 59.6% | 63.9% | 64.4% | 66.2% | 63.1% | 66.9% | 64.7% | 65.6% | 66.6% | 65.5% | 65.5% |
| R&D | 66M | 70M | 65M | 69M | 85M | 87M | 93M | 93M | 110M | 137M | 155M | 172M | 173M |
| SG&A | 683M | 713M | 723M | 799M | 973M | 996M | 993M | 1.2B | 1.3B | 1.5B | 1.5B | 1.6B | 1.9B |
| EBIT | 306M | 237M | 324M | 429M | 403M | 547M | 312M | 506M | 508M | 533M | 706M | 683M | 498M |
| Op. Margin | 17.8% | 13.2% | 16.5% | 20.1% | 15.9% | 20.6% | 12.8% | 17.3% | 15.3% | 14.8% | 18.1% | 16.7% | 11.8% |
| Net Income | 270M | 204M | 274M | 373M | 140M | 467M | 238M | 2.9B | 386M | 294M | 392M | 375M | 236M |
| Net Margin | 15.7% | 11.3% | 13.9% | 17.4% | 5.5% | 17.6% | 9.8% | 100.8% | 11.7% | 8.2% | 10.1% | 9.2% | 5.6% |
| Non-Recurring | 0 | 0 | -31M | -6.1M | -5.1M | -7.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 8.5% | 5.7% | 7.4% | 9.9% | 5.1% | 10.1% | 5.4% | 43.5% | 4.5% | 3.8% | 4.6% | 4.3% | 2.7% |
| ROE | 10.8% | 7.8% | 10.2% | 12.7% | 4.3% | 13.5% | 6.4% | 54.7% | 5.5% | 4.0% | 5.0% | 4.6% | 2.9% |
| ROA | 7.1% | 4.6% | 6.1% | 8.0% | 2.6% | 7.5% | 3.7% | 36.0% | 3.7% | 2.5% | 3.3% | 3.0% | 1.9% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 455M | 391M | 510M | 594M | 669M | 713M | 487M | 739M | 692M | 608M | 709M | 796M | 953M |
| Free Cash Flow | 217M | 148M | 357M | 466M | 475M | 421M | 176M | 524M | 450M | 215M | 288M | 434M | 570M |
| Owner Earnings | 280M | 167M | 281M | 368M | 351M | 397M | 162M | 386M | 292M | 178M | 259M | 348M | 503M |
| CapEx | 238M | 243M | 153M | 127M | 194M | 292M | 310M | 214M | 242M | 393M | 421M | 362M | 383M |
| Maint. CapEx | 138M | 191M | 198M | 188M | 275M | 281M | 287M | 309M | 346M | 368M | 375M | 377M | 385M |
| Growth CapEx | 100M | 52M | 0 | 0 | 0 | 11M | 23M | 0 | 0 | 25M | 46M | 0 | 0 |
| D&A | 138M | 191M | 198M | 188M | 275M | 281M | 287M | 309M | 346M | 368M | 375M | 377M | 385M |
| CapEx/OCF | 52.3% | 62.2% | 29.9% | 21.4% | 28.9% | 41.0% | 63.8% | 29.0% | 35.0% | 64.6% | 59.4% | 45.5% | 40.2% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 2.9M | 2.9M | 2.9M | 2.9M | 2.9M | 3.0M | 3.0M | 3.0M | 3.0M | 3.0M | 0 | 0 | 0 |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A |
| Share Buybacks | 76M | 67M | 0 | 55M | 0 | 156M | 48M | 25M | 79M | 0 | 0 | 290M | 358M |
| Buyback Yield | 1.0% | 0.9% | N/A | 0.5% | N/A | 1.1% | 0.3% | 0.1% | 0.6% | N/A | N/A | 2.0% | 2.6% |
| Stock-Based Comp | 37M | 33M | 30M | 37M | 43M | 35M | 38M | 44M | 54M | 62M | 75M | 71M | 65M |
| Debt Repayment | 1.7B | 1.4B | 1.5B | 1.4B | 1.9B | 1.9B | 3.2B | 1.4B | 562M | 2.0B | 3.5B | 3.2B | 3.2B |
| Balance Sheet | |||||||||||||
| Net Debt | 1.4B | 1.3B | 1.4B | 1.1B | 2.0B | 1.7B | 1.7B | 1.4B | 3.0B | 2.5B | 2.5B | 2.4B | 2.3B |
| Cash & Equiv. | 25M | 16M | 101M | 89M | 78M | 89M | 116M | 96M | 138M | 121M | 108M | 111M | 139M |
| Long-Term Debt | 1.3B | 1.1B | 1.1B | 1.1B | 2.0B | 1.3B | 1.4B | 1.4B | 2.3B | 2.5B | 2.5B | 2.5B | 1.9B |
| Debt/Equity | 0.54 | 0.51 | 0.57 | 0.37 | 0.62 | 0.50 | 0.47 | 0.21 | 0.44 | 0.35 | 0.32 | 0.31 | 0.30 |
| Interest Coverage | 38.5 | 13.1 | 12.4 | 12.8 | 4.9 | 8.0 | 8.5 | 21.9 | 8.9 | 5.1 | 6.2 | 6.8 | 5.3 |
| Equity | 2.6B | 2.7B | 2.7B | 3.2B | 3.3B | 3.6B | 3.8B | 6.9B | 7.2B | 7.6B | 8.1B | 8.2B | 8.2B |
| Total Assets | 4.5B | 4.5B | 4.5B | 4.9B | 6.1B | 6.3B | 6.7B | 9.6B | 11.5B | 11.7B | 12.3B | 12.4B | 12.5B |
| Total Liabilities | 1.9B | 1.8B | 1.8B | 1.7B | 2.8B | 2.6B | 2.9B | 2.7B | 4.3B | 4.1B | 4.2B | 4.2B | 4.2B |
| Intangibles | 454M | 411M | 441M | 505M | 1.5B | 1.4B | 1.3B | 1.3B | 1.9B | 1.7B | 1.8B | 1.6B | 1.5B |
| Retained Earnings | 1.6B | 1.8B | 2.0B | 2.4B | 2.6B | 3.0B | 3.3B | 6.2B | 6.6B | 6.9B | 7.3B | 7.6B | 7.7B |
| Working Capital | 349M | 273M | 394M | 557M | 554M | 53M | 270M | 733M | 253M | 736M | 929M | 994M | 495M |
| Current Assets | 792M | 841M | 937M | 953M | 1.1B | 1.2B | 1.3B | 1.5B | 1.5B | 1.7B | 2.0B | 2.1B | 2.3B |
| Current Liabilities | 442M | 569M | 543M | 396M | 537M | 1.1B | 1.0B | 732M | 1.3B | 969M | 1.0B | 1.1B | 1.8B |
| Per Share Data | |||||||||||||
| EPS | 1.38 | 1.04 | 1.40 | 1.88 | 0.70 | 2.33 | 1.20 | 14.79 | 1.95 | 1.49 | 1.96 | 1.87 | 1.20 |
| Owner EPS | 1.43 | 0.85 | 1.44 | 1.86 | 1.76 | 1.99 | 0.82 | 1.94 | 1.48 | 0.90 | 1.29 | 1.74 | 2.58 |
| Book Value | 13.12 | 13.57 | 13.75 | 16.01 | 16.61 | 18.13 | 19.29 | 34.87 | 36.34 | 38.12 | 40.39 | 41.10 | 42.27 |
| Cash Flow/Share | 2.32 | 1.99 | 2.60 | 2.99 | 3.36 | 3.56 | 2.45 | 3.71 | 3.51 | 3.07 | 3.54 | 3.97 | 3.18 |
| Dividends/Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 195.9M | 196.6M | 196.0M | 198.4M | 199.1M | 200.1M | 198.3M | 199.1M | 197.4M | 198.1M | 200.2M | 200.5M | 194.9M |
| Valuation | |||||||||||||
| P/E Ratio | 29.1 | 35.9 | 31.3 | 32.5 | 88.1 | 30.4 | 69.3 | 7.0 | 35.5 | 51.8 | 53.8 | 38.4 | 58.7 |
| P/FCF | 36.2 | 49.4 | 24.0 | 26.0 | 25.9 | 33.7 | 93.8 | 39.6 | 30.2 | 70.7 | 73.3 | 33.2 | 24.1 |
| EV/EBIT | 30.0 | 36.5 | 30.6 | 30.5 | 35.3 | 30.0 | 59.3 | 43.7 | 32.7 | 33.1 | 33.3 | 24.5 | 32.2 |
| Price/Book | 3.1 | 2.7 | 3.2 | 3.8 | 3.7 | 3.9 | 4.3 | 3.0 | 1.9 | 2.0 | 2.6 | 1.7 | 1.7 |
| Price/Sales | 3.9 | 4.6 | 3.9 | 4.9 | 4.7 | 5.5 | 6.4 | 6.6 | 5.3 | 4.8 | 4.9 | 4.0 | 3.2 |
| FCF Yield | 2.8% | 2.0% | 4.2% | 3.9% | 3.9% | 3.0% | 1.1% | 2.5% | 3.3% | 1.4% | 1.4% | 3.0% | 4.2% |
| Market Cap | 7.9B | 7.3B | 8.6B | 12.1B | 12.3B | 14.2B | 16.5B | 20.7B | 13.7B | 15.3B | 21.1B | 14.4B | 13.7B |
| Avg. Price | 34.53 | 41.94 | 39.63 | 52.76 | 59.91 | 73.16 | 78.03 | 97.44 | 89.00 | 87.38 | 95.01 | 81.95 | 70.31 |
| Year-End Price | 40.10 | 37.18 | 43.78 | 61.04 | 61.91 | 70.96 | 83.35 | 104.15 | 68.84 | 76.72 | 105.51 | 71.75 | 70.31 |
COOPER COMPANIES, INC. passes 6 of 9 quality checks, suggesting mixed fundamentals.
COOPER COMPANIES, INC. trades at 37.6x trailing earnings, compared to its 15-year median P/E of 36.9x, suggesting it is currently Fair relative to its historical range. On a free-cash-flow basis, the stock trades at 31.8x vs a median of 33.4x. The company's 5-year average ROIC is 12.1% with a gross margin of 65.9%. Total shareholder yield (buybacks) is 2.6%. At current prices, the estimated annualized return to fair value is -4.6%.
COOPER COMPANIES, INC. (COO) has a net profit margin of 9.2%. This is a modest margin.
COOPER COMPANIES, INC. (COO) generated $434 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
COOPER COMPANIES, INC. (COO) has a debt-to-equity ratio of 0.31. This indicates a conservatively financed balance sheet.
COOPER COMPANIES, INC. (COO) reported earnings per share (EPS) of $1.87 in its most recent fiscal year.
COOPER COMPANIES, INC. (COO) has a return on equity (ROE) of 4.6%. This indicates moderate shareholder returns.
COOPER COMPANIES, INC. (COO) has a 5-year average gross margin of 65.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 18 years of financial data for COOPER COMPANIES, INC. (COO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
COOPER COMPANIES, INC. (COO) has a book value per share of $41.10, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management expects CooperVision's Asia-Pacific region, which has faced softness from market weakness and legacy product rationalization, to stabilize and return to growth in the second half of fiscal 2026 as new regional leadership executes on product launches and contract wins. The company anticipates the global contact lens market will grow at the low end of the historical 4%–6% range, with regional softness in Asia-Pacific viewed as temporary and tied to economic pressures in China and Japan rather than fundamental demand deterioration. CooperSurgical's fertility business is expected to rebound with mid-single-digit growth in the back half of 2026, supported by improving clinic investment cycles, delayed childbirth trends, and expanding access to care, while the long-term outlook remains positive driven by a strong innovation pipeline and increasing awareness of fertility solutions. The company is pursuing disciplined capital allocation, prioritizing share repurchases and debt reduction while continuing to invest in growth initiatives and operational efficiency improvements through AI-enabled systems and supply chain optimization.
Based on recent SEC filings and earnings calls, COOPER COMPANIES, INC. (COO) has provided the following forward guidance: Revenue: $4.28 billion–$4.32 billion (FY2026); CooperVision Revenue: $2.88 billion–$2.91 billion (FY2026); CooperSurgical Revenue: $1.4 billion–$1.41 billion (FY2026); EPS: $4.58–$4.66 (FY2026); Free Cash Flow: ~$650 million (FY2026), plus 7 additional metrics.
| FY2026 |
| Free Cash Flow (3-year outlook) | >$2.2 billion | FY2026–FY2028 |
Revenue (FY2026): “we've updated expectations with revenues expected to be roughly $4.28 billion-$4.32 billion, reflecting growth of 5%-6% or organic growth of 3.5%-4.5%”
CooperVision Revenue (FY2026): “CooperVision revenue is expected to be in the range of roughly $2.88 billion-$2.91 billion, up 5%-6%, or 3.5%-4.5% organically”
CooperSurgical Revenue (FY2026): “CooperSurgical remains essentially unchanged, with a range of roughly $1.4 billion-$1.41 billion, up 4%-5% as reported and organically”
EPS (FY2026): “For earnings, we're maintaining guidance at $4.58-$4.66”
Free Cash Flow (FY2026): “we're increasing our 2026 free cash flow outlook to roughly $650 million, excluding any litigation payouts”
Interest Expense (FY2026): “Interest expense is expected to be around $85 million”
Effective Tax Rate (FY2026): “the effective tax rate is expected to be around 15.5%”
Tariff Impact (FY2026): “Regarding tariffs, our guidance assumes approximately $22 million this fiscal year”